SGLT2 Inhibitor Study for Type 2 Diabetes and Kidney Disease
This study is looking at how Canagliflozin (INVOKANA), an FDA-approved SGLT2 inhibitor, affects kidney health in people with Type 2 Diabetes and early Diabetic Kidney Disease. All 20 participants will take 100 mg of Canagliflozin daily for six months. We're looking for adults aged 18-80 who have had Type 2 Diabetes for at least three years and have specific kidney function levels (eGFR between 45 and 90 ml/min/1.73m2, and a urinary albumin-to-creatinine ratio less than 3000 mg/g). The main goal is to see if Canagliflozin changes the width of the kidney's filtering membranes (glomerular basement membrane) and the expansion of kidney tissue (mesangial expansion) over six months.
- Study design
- This is an open-label, non-randomized interventional study with 20 planned participants. It is not specified which phase the study is in.
- What's involved
- You would have a screening visit, including lab tests and a kidney ultrasound. Then, at the start, you'd have a kidney MRI and a kidney biopsy, followed by daily Canagliflozin for six months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes are measured at baseline and after 6 months, which is the duration of the drug treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06291155
Mechanism of SGLT2 Inhibition in the Kidney
Recruiting
PHASE4Ages 18–80InterventionalDiagnosticUniversity of MichiganInvestigator-initiated
~20 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:SGLT2 inhibitor
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Glomerular basement membrane (GBM) width and mesangial expansion
Measured over Baseline and 6 months
Conditions
Where it's being run
1 sites across 1 statesMichigan1
Study leadership
- Markus Bitzer, MD · PRINCIPAL_INVESTIGATOR · Professor of Internal Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Aged 18-80 years.
The lower age limit was set so renal function test results would not reflect changes associated with growth.
Diagnosis of type 2 diabetes for ≥ 3 years.
Estimated GFR \>45 and \< 90 ml/min/1.73m2 as determined from the CKD-EPI equation using serum creatinine (Levey et al., 2009)
A screening urinary albumin-to-creatinine ratio \<3000 mg/g.
Willingness to participate after receiving a thorough explanation of the study.
Participants receiving a RAAS inhibitor must have been receiving the drug at maximum tolerable dose for at least 3 months prior to the study baseline examination.
Participants receiving a GLP-1 receptor agonist must have been receiving the drug for at least 3 months prior to the study baseline examination.
Participants must meet the current clinical guidelines for prescribing SGLT2 inhibitors, to maintain FDA-approved standards
Exclusion
Clinically significant disorders of the liver \[cirrhosis, portal hypertension, hepatitis, increased bilirubin (≥1.5 mg/dl), active or uncontrolled cardiovascular disease, symptomatic peripheral vascular disease, (i.e. intermittent claudication), pulmonary diseases (including uncontrolled asthma and restrictive or obstructive lung disease requiring therapy), renal-urinary disorders (calculi, urinary tract obstruction, glomerulonephritis, chronic infection), gastrointestinal disorders (nausea, vomiting, diarrhea or anorexia sufficient to cause weight loss or wasting), or hematocrit levels ≤30 percent in women or ≤35 percent in men.
Prior and ongoing treatment with SGLT2 inhibitors
Renovascular or malignant hypertension; uncontrolled hypertension (systolic blood pressure ≥150 or diastolic ≥90 mm Hg)
Hematuria of unknown etiology.
Prior to entry into the study, any participant with hematuria should be evaluated, the etiology established and documented, and treatment rendered as appropriate.
Chronic debilitating disorders with or without treatment (e.g., systemic lupus erythematosus \[SLE\], cancer, amyloidosis, and chronic infection) that would interfere with the assessment of kidney function or that might reduce the chances of survival for a sufficient length of time to evaluate the efficacy of treatment.
Currently receiving a drug regimen that includes steroids, immunosuppressants, or investigational new drugs not associated with this trial.
Pregnancy.
SGLT2 inhibitors are not recommended during the second or third trimester of pregnancy. Moreover, we do not wish to expose pregnant women to conscious sedation that is used during the kidney biopsies.. Women of childbearing potential must have a negative pregnancy test prior to entry and every 2 months during the study and agree to using an effective form of contraception throughout the study, such as the oral contraceptive pill or an intrauterine device. Women who are planning a pregnancy in the next three years will be excluded.
Known hypersensitivity to canagliflozin or iodine.
Bleeding disorders or requirements for anticoagulation or platelet inhibitors which cannot be safely interrupted since kidney biopsies cannot be performed safely in these individuals.
Massive obesity with body mass index ≥45 kg/m².
Kidney biopsies are more technically difficult with massive obesity.
Allergy to iodine-containing contrast material or shellfish.
Non-diabetic kidney disease - based on clinical history or kidney biopsy examination.
History of osteoporotic fracture.
History of lower-limb amputation irrespective of etiology
Conditions likely to interfere with informed consent or compliance with the protocol.
Known solitary kidney
Size of one or both kidneys on ultrasound \< 9 cm (small kidney size is concerning for renal atrophy due to underlying kidney disease) or \> 2 cm discrepancy between left and right kidney sizes based on largest longitudinal diameter
Current use of UGT enzyme inducters, lithium, and digoxin
Blood urea nitrogen (BUN) \> 80 gm/dL
INR \> 1.4 (a)
PTT \> 35 seconds (a)
Platelet count \< 100,000 uL (a)
Hemoglobin (Hgb) \< 10 mg/dL (a)
Hydronephrosis or other important renal ultrasound findings such as significant stone disease
What this trial measures
- Glomerular basement membrane (GBM) width and mesangial expansionBaseline and 6 months
Measured by morphometric examination of kidney tissue